Amtagvi (lifileucel) - MEDICAID - FLORIDA

This policy covers Amtagvi (lifileucel), an autologous tumor‑infiltrating lymphocyte (TIL) immunotherapy for adults with unresectable or metastatic melanoma. Coverage is limited to individuals ≥18 years who have progressed on a PD‑1 inhibitor (and, if BRAF V600–mutant, a BRAF inhibitor ± MEK inhibitor), requires medical‑director review/prior authorization through the Corporate Transplant Department, excludes other indications and pregnancy/intent to reproduce, and notes that evidence is limited.

"Documentation verifying patient age (18 years of age or older)"

Sign up to see full coverage criteria, indications, and limitations.